Results

Total Results: over 10,000 records

Showing results for "author year description".

  1. www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
    April 01, 2016 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No. q. … Population – pre-school age children (1 year through 5 years) (specify age range): No. r. … During the 1990s, the diabetes rate increased by an average of 3 percent per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American Dietetic Association, 2008).
  2. www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
    April 01, 2016 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No. q. … Population – pre-school age children (1 year through 5 years) (specify age range): No. r. … During the 1990s, the diabetes rate increased by an average of 3 percent per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American Dietetic Association, 2008).
  3. www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
    April 01, 2016 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No. q. … Population – pre-school age children (1 year through 5 years) (specify age range): No. r. … During the 1990s, the diabetes rate increased by an average of 3 percent per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American Dietetic Association, 2008).
  4. www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
    April 01, 2016 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No. q. … Population – pre-school age children (1 year through 5 years) (specify age range): No. r. … During the 1990s, the diabetes rate increased by an average of 3 percent per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American Dietetic Association, 2008).
  5. www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
    April 01, 2016 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No. q. … Population – pre-school age children (1 year through 5 years) (specify age range): No. r. … During the 1990s, the diabetes rate increased by an average of 3 percent per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American Dietetic Association, 2008).
  6. www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
    April 01, 2016 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No. q. … Population – pre-school age children (1 year through 5 years) (specify age range): No. r. … During the 1990s, the diabetes rate increased by an average of 3 percent per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American Dietetic Association, 2008).
  7. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-170-fullreport.pdf
    April 01, 2016 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … Population – infants (29 days to 1 year) (specify age range): No. q. … Population – pre-school age children (1 year through 5 years) (specify age range): No. r. … During the 1990s, the diabetes rate increased by an average of 3 percent per year, but between 2000 … and 2002, the pace of increase rose to 6 percent per year (American Dietetic Association, 2008).
  8. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-193-disposition-comments-naloxone.pdf
    November 27, 2017 - There is a need to account for the fact that the drugs available on the street tend to vary from year … to year and have recently focused on high potency, inexpensive synthetic opioids and thus data from … Healthcare Research and Quality (AHRQ), Rockville, MD, with the finding and views being that of the author … & Affiliation Section Comment Response Public Reviewer #1, Joi Kelly General Comments The author … This includes description of the same results in various discussion sections provided.
  9. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-193-disposition-comments-naloxone.pdf
    November 27, 2017 - There is a need to account for the fact that the drugs available on the street tend to vary from year … to year and have recently focused on high potency, inexpensive synthetic opioids and thus data from … Healthcare Research and Quality (AHRQ), Rockville, MD, with the finding and views being that of the author … & Affiliation Section Comment Response Public Reviewer #1, Joi Kelly General Comments The author … This includes description of the same results in various discussion sections provided.
  10. www.uspreventiveservicestaskforce.org/home/getfilebytoken/h-w99jVsodSL33kV2h2_qW
    April 17, 2018 - Author Audio Interview Related article Author/Group Information: The US Preventive Services Task Force … Corresponding Author: David C. … USPSTF Levels of Certainty Regarding Net Benefit Level of Certainty Description High The available … risk assessment with multicomponent interventions in older adults who have had 2 falls in the past yearAuthor Contributions: Dr Grossman had full access to all of the data in the study and takes responsibility
  11. effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
    April 01, 2013 - The findings and conclusions in this document are those of the author(s), who are responsible for its … Considerations Interrupted Time Series (Without a Comparison Group) Design Description A cohort of … Considerations RCT Design Description Individual patients randomly assigned to either multimodal … Considerations RCT Design Description Individual patients randomly assigned to either combination … Cephalalgia. 2007 May;27(5):469; author reply -70. PMID: 17448186. 18. U.S.
  12. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
    April 01, 2013 - The findings and conclusions in this document are those of the author(s), who are responsible for its … Considerations Interrupted Time Series (Without a Comparison Group) Design Description A cohort of … Considerations RCT Design Description Individual patients randomly assigned to either multimodal … Considerations RCT Design Description Individual patients randomly assigned to either combination … Cephalalgia. 2007 May;27(5):469; author reply -70. PMID: 17448186. 18. U.S.
  13. www.uspreventiveservicestaskforce.org/home/getfilebytoken/_ZPNC3vqdS3R-ggXro6UAM
    April 05, 2016 - (D recommendation) JAMA. 2016;315(13):1372-1377. doi:10.1001/jama.2016.2638 Editorial page 1343 Author … Corresponding Author: Albert L. Siu, MD, MSPH (chair@uspstf.net). … USPSTF Levels of Certainty Regarding Net Benefit Level of Certainty Description High The available … emergency department visits.4 Health care costs associated with COPD are an estimated $32 billion per year … However, rates of COPD exacerbation were extremely low at baseline (<1 episode per year), even among
  14. www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
    February 01, 2018 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1 year. q. … Research Evidence Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study sample
  15. www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
    February 01, 2018 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1 year. q. … Research Evidence Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study sample
  16. www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
    February 01, 2018 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1 year. q. … Research Evidence Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study sample
  17. www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
    February 01, 2018 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1 year. q. … Research Evidence Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study sample
  18. www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
    February 01, 2018 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1 year. q. … Research Evidence Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study sample
  19. www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
    February 01, 2018 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1 year. q. … Research Evidence Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study sample
  20. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-229-fullreport.pdf
    February 01, 2018 - Measure Description Please provide a non-technical description of the measure that conveys what it measures … The results of a 9-year retrospective study (Han, et al., 2003) indicated that 29 percent of infants … Population – infants (29 days to 1 year) (specify age range): Yes; ages 29 days to 1 year. q. … Research Evidence Research evidence should include a brief description of the evidence base for valid … Include results of all tests of validity and reliability, including description(s) of the study sample